Ursprung des Netzwerks ersten Grades von René Goedkoop
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von René Goedkoop
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal | |
AC IMMUNE SA | Pharmaceuticals: Major | Investor Relations Contact | |
SOCIÉTÉ GÉNÉRALE | Regional Banks | Corporate Officer/Principal | |
BARCLAYS PLC | Investment Banks/Brokers | Director/Board Member | |
UCB | Pharmaceuticals: Major | Corporate Officer/Principal | |
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland Gesellschaft für Industriebeteiligungen mbH (3i Deutschland) is the German private equity subsidiary of 3i Group Plc (LSE: III) in Great Britain. Established in Frankfurt in 1984, the firm invests in small and medium-sized German companies at all stages of development, from start-ups to established businesses. In addition to the Frankfurt office, 3i Deutschland has offices in Munich and Stuttgart. They drive their investment focus and decisions from their Frankfurt and Munich offices, and the team collaborates with Swiss colleagues in Zurich and 3i's network across Europe, Asia and the U.S. to invest in a wide range of industry sectors. | Investment Managers | Private Equity Investor | |
Imperial College London | College/University | Undergraduate Degree | |
Bryan, Garnier & Co Ltd.
Bryan, Garnier & Co Ltd. Investment Banks/BrokersFinance Bryan, Garnier & Co Ltd. is a European, full-service growth-focused independent investment bank for technology, healthcare, consumer, and business services companies. The private company is based in London, UK, and has a global presence of subsidiaries in several regions. The British company is well-positioned in a capex intensive industry that is increasingly dynamic both in capital raising and M & A, driven by the 4th Industrial Revolution. Bryan Garnier is the world's leading independent full-service investment bank for European healthcare and technology-led companies and their investors. The company is focused on new disruptive technologies and alternative production models in a variety of domains geared towards fighting climate change and environmental degradation. The consumer sector is transformed across its segments by the way digital natives relate to brands, products, and the environment. The company was founded in 1996 by Olivier Marie Paul Garnier de Falletans. | Investment Banks/Brokers | Analyst-Equity | |
Monash University
Monash University Other Consumer ServicesConsumer Services Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia. | College/University | Doctorate Degree | |
University of Durham | College/University | Masters Business Admin | |
CELLECTIS S.A. | Pharmaceuticals: Major | Director/Board Member | |
Allergan Ltd.
Allergan Ltd. Pharmaceuticals: MajorHealth Technology Allergan Ltd. provides eye care and specialty pharmaceutical products. It develops pharmaceutical products used for treatment of eye and skin care medications and neurological disorders. The firm develops products for glaucoma, dry eye, blepharospasm, cervical, dystonia, hemi-facial spasm, post-stroke spasticity and cerebral palsy. The company was founded in 1977 and is headquartered in Marlow, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Zeus Capital Ltd. (Broker) | Investment Banks/Brokers | Analyst-Equity | |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The private company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
DERMIRA, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The private company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Pharmaceuticals: Major | Chief Executive Officer | |
neurocare group AG
neurocare group AG Medical SpecialtiesHealth Technology Neurocare Group AG manufactures neurosurgical instruments and monitoring devices. The company is based in Ilmenau, Germany. The German company was founded in 2014 by Thomas Georg Mechtersheimer. Thomas Georg Mechtersheimer has been the CEO since 2014. | Medical Specialties | Investor Relations Contact | |
CONNECT BIOPHARMA HOLDINGS LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal | |
Artemis Catalyst Ltd. | Founder |
Statistik
International
Vereinigtes Königreich | 11 |
Deutschland | 5 |
Frankreich | 3 |
Schweiz | 2 |
Belgien | 2 |
Sektoral
Health Technology | 11 |
Finance | 8 |
Consumer Services | 4 |
Operativ
Corporate Officer/Principal | 9 |
Analyst-Equity | 4 |
Investor Relations Contact | 4 |
Public Communications Contact | 3 |
Director/Board Member | 3 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Gary Waanders | 8 |
Selwyn Ho | 8 |
Axel-Sven Malkomes | 7 |
Pamela Keck | 2 |
- Börse
- Insiders
- René Goedkoop
- Unternehmensverbindungen